Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Recurrence risk high regardless of VTE classification
Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4
Key clinical point: Significant recurrence risk among all three classifications of VTE indicates a need to rethink how patients are categorized.
Major finding: At 10-year follow-up, recurrence rates per 100 person-years were 3.70 for patients with cancer-related VTE, 2.84 for patients with unprovoked VTE, and 2.22 for patients with provoked VTE.
Study details: An observational cohort study of 73,993 Danish patients with incident venous thromboembolism during January 2000–December 2015.
Disclosures: The study was partially funded by a grant from the Obel Family Foundation. Some authors reported financial disclosures related to Janssen, Bayer, Roche, and others.
Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4
